drugset / Trial / NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Non-randomizedSequentialOpen-labelBasic science
Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.
Timeline
- Start
- 2022-07-08
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caffeine | Small molecule | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Retatrutide | Protein / enzyme biologic | — | Subcutaneous |
| Subject | Warfarin | Small molecule | — | Oral |